Theraclion (XPAR:ALTHE) Notes Receivable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALTHE Theraclion XPAR:ALTHE
27 GF Score
Price €0.58
GF Value €0.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Theraclion Notes Receivable?

Theraclion XPAR:ALTHE -2.19% 27 Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALTHE with a GF Score™ of 27/100 and a GF Value™ of €0.26 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Theraclion's Notes Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Theraclion Notes Receivable Historical Data

* Premium members only.

The historical data trend for Theraclion's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theraclion Notes Receivable Chart

Theraclion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Theraclion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALTHE
27GF Score
Theraclion XPAR:ALTHE
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theraclion Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Theraclion (XPAR:ALTHE) has a Notes Receivable of €0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Theraclion and its competitors.
Is Theraclion's Notes Receivable too high?
Theraclion's current Notes Receivable is €0.00 Mil. Overall, Theraclion has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theraclion's Notes Receivable compare to ABT and SYK?
Theraclion's Notes Receivable of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Theraclion and its competitors. Theraclion's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theraclion stock overvalued right now?
Based on GuruFocus' analysis, Theraclion (XPAR:ALTHE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.58 — trading 123.5% above its estimated fair value. The current Notes Receivable is €0.00 Mil. Theraclion's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Theraclion (XPAR:ALTHE), the current Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theraclion (XPAR:ALTHE) Overvalued in 2026?

Based on GuruFocus' analysis, Theraclion stock appears to be overvalued. The current stock price of €0.58 is trading 123.5% above its estimated GF Value™ of €0.26. GuruFocus considers Theraclion to be Significantly Overvalued.

Key valuation signals for XPAR:ALTHE:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €0.26 vs. price of €0.58 (123.5% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the XPAR:ALTHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theraclion Business Description

Other Exchanges 941:Germany
Address 244 Avenue Pierre Brossolette, Immeuble Le Vaillant, Malakoff, Paris, FRA, 92240
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
27GF Score

Get the complete analysis for XPAR:ALTHE

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price
€0.26
GF Value